Among 198 drugs, patients in the high-risk group were more sensitive to drugs such as pan-Akt pathway inhibitor (uprosertib) and a selective PI3Kδ inhibitor (AMG-319), as a critical pathway and molecule modulating the immune response in vitro and in vivo, which can inhibit cytokine regulation, PD-L1 expression, and tumor-infiltrating Regulatory T cells (Treg), and currently used in the treatment of breast cancer, colon cancer and B cell malignancies31-33. This evidence concerns the gene AKT1 and breast carcinoma.